FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557055981> ?p ?o ?g. }

• W2557055981 abstract "Background Recently, it has been described in many reports that B cell has important roles in connective tissue disease (CTD). Rituximab (RTX), anti-CD20 monoclonal antibody is widely known as effective for patients with several autoimmune hematological disorders including thrombotic microangiopathy (TMA) through not only B cell depletion but reducing antigen-presenting cell function, complement hyperactivation, release of inflammatory cytokines and abnormal auto-reactive T cell response through co-stimulatory signals. 1) TMA is developed in CTD occasionally. CTD-TMA especially with normal activity of von Willebrand factor cleaving protease, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member-13 (ADAMTS-13) is often resistant for plasma exchange (PE) conducted for thrombotic thrombocytopenic purpura with ADAMTS-13 inhibitor and lack of ADAMTS-13 activity as a first-line treatment. 2) It has been reported that the autoantibodies other than ADAMTS-13 inhibitor, complement hyperactivation, and excessive inflammatory cytokines production associated with refractory TMA. 3) Objectives We investigate the efficacy and the long-term prognosis of RTX treatment for refractory TMA associated with CTD. Methods We enrolled 7 CTD-TMA patients (SLE; 3, SS; 2, MCTD; 1, DM; 1) with refractory to PE treatment between 2006 and 2015. We examined the ADAMTS-13 activity, its inhibitor and ultra-large von Willebrand factor multimers (UL-VWFMs) at TMA onset. RTX was given 375mg/m 2 per a dose. We defined complete response (CR) as platelet counts >150×10 9 /l for more than 3 consecutive days, with normal levels of serum LDH and an absence of TMA-related symptoms. We considered CR continued more than 30 days after RTX treatment as remission. In addition, we investigated as follow subjects; duration from initial RTX treatment to CR, duration of sustained CR, relapse and adverse events. Results No abnormality of ADAMTS-13 activity was observed 6 patients. The thrombocytopenia was improved immediately within 2–3 weeks after the initiation of RTX and hemolytic anemia and neuropsychiatric manifestations were improved following after the recovery of thrombocytopenia, respectively. 6 patients could achieve CR. They who achieved CR all have sustained long-term remission by only 1 or 2 doses of RTX administration and there was no relapse. RTX was partial response for 1 patient with insufficient recovery of thrombocytopenia but detectable serum haptoglobin and she was reported with controllable bacterial pneumonia. Conclusions We suggest that RTX treatment has efficacy with high response rate and long-term remission for the refractory CTD-TMA patients. Moreover, RTX treatment can be the first-line treatment for CTD-TMA. References Roberto Stasi. Rituximab in autoimmune hematologic disease: not just a matter of B cells. Semin Hematol. 2010; 47: 170–179. Tomomi Matsuyama, Masataka Kuwana, Masanori Matsumoto, et.al. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost. 2009; 102: 371–378. Marina Noris, Federica Mescia, Giuseppe Remuzzi. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat. Rev. Nephrol. 2012; 8: 622–633. Disclosure of Interest None declared" @default.
• W2557055981 created "2016-11-30" @default.
• W2557055981 creator A5001690732 @default.
• W2557055981 creator A5007124268 @default.
• W2557055981 creator A5018382490 @default.
• W2557055981 creator A5019020114 @default.
• W2557055981 creator A5020106035 @default.
• W2557055981 creator A5025432812 @default.
• W2557055981 creator A5066776386 @default.
• W2557055981 creator A5071465896 @default.
• W2557055981 creator A5075626153 @default.
• W2557055981 date "2016-06-01" @default.
• W2557055981 modified "2023-09-24" @default.
• W2557055981 title "THU0286 The Efficacy and The Long-Term Prognosis of Rituximab for Refractory Thrombotic Microangiopathy Associated with Connective Tissue Diseases" @default.
• W2557055981 doi "https://doi.org/10.1136/annrheumdis-2016-eular.3139" @default.
• W2557055981 hasPublicationYear "2016" @default.
• W2557055981 type Work @default.
• W2557055981 sameAs 2557055981 @default.
• W2557055981 citedByCount "0" @default.
• W2557055981 crossrefType "journal-article" @default.
• W2557055981 hasAuthorship W2557055981A5001690732 @default.
• W2557055981 hasAuthorship W2557055981A5007124268 @default.
• W2557055981 hasAuthorship W2557055981A5018382490 @default.
• W2557055981 hasAuthorship W2557055981A5019020114 @default.
• W2557055981 hasAuthorship W2557055981A5020106035 @default.
• W2557055981 hasAuthorship W2557055981A5025432812 @default.
• W2557055981 hasAuthorship W2557055981A5066776386 @default.
• W2557055981 hasAuthorship W2557055981A5071465896 @default.
• W2557055981 hasAuthorship W2557055981A5075626153 @default.
• W2557055981 hasConcept C111368507 @default.
• W2557055981 hasConcept C125533998 @default.
• W2557055981 hasConcept C126322002 @default.
• W2557055981 hasConcept C127313418 @default.
• W2557055981 hasConcept C159654299 @default.
• W2557055981 hasConcept C203014093 @default.
• W2557055981 hasConcept C2776874634 @default.
• W2557055981 hasConcept C2777878052 @default.
• W2557055981 hasConcept C2778585876 @default.
• W2557055981 hasConcept C2779134260 @default.
• W2557055981 hasConcept C2779394231 @default.
• W2557055981 hasConcept C2780653079 @default.
• W2557055981 hasConcept C2780921031 @default.
• W2557055981 hasConcept C71924100 @default.
• W2557055981 hasConcept C89560881 @default.
• W2557055981 hasConceptScore W2557055981C111368507 @default.
• W2557055981 hasConceptScore W2557055981C125533998 @default.
• W2557055981 hasConceptScore W2557055981C126322002 @default.
• W2557055981 hasConceptScore W2557055981C127313418 @default.
• W2557055981 hasConceptScore W2557055981C159654299 @default.
• W2557055981 hasConceptScore W2557055981C203014093 @default.
• W2557055981 hasConceptScore W2557055981C2776874634 @default.
• W2557055981 hasConceptScore W2557055981C2777878052 @default.
• W2557055981 hasConceptScore W2557055981C2778585876 @default.
• W2557055981 hasConceptScore W2557055981C2779134260 @default.
• W2557055981 hasConceptScore W2557055981C2779394231 @default.
• W2557055981 hasConceptScore W2557055981C2780653079 @default.
• W2557055981 hasConceptScore W2557055981C2780921031 @default.
• W2557055981 hasConceptScore W2557055981C71924100 @default.
• W2557055981 hasConceptScore W2557055981C89560881 @default.
• W2557055981 hasLocation W25570559811 @default.
• W2557055981 hasOpenAccess W2557055981 @default.
• W2557055981 hasPrimaryLocation W25570559811 @default.
• W2557055981 hasRelatedWork W1566884808 @default.
• W2557055981 hasRelatedWork W173126450 @default.
• W2557055981 hasRelatedWork W1980805976 @default.
• W2557055981 hasRelatedWork W1991543435 @default.
• W2557055981 hasRelatedWork W2017957905 @default.
• W2557055981 hasRelatedWork W2058798449 @default.
• W2557055981 hasRelatedWork W2059481007 @default.
• W2557055981 hasRelatedWork W2075485887 @default.
• W2557055981 hasRelatedWork W2287487617 @default.
• W2557055981 hasRelatedWork W2320035658 @default.
• W2557055981 hasRelatedWork W2321267637 @default.
• W2557055981 hasRelatedWork W2333214548 @default.
• W2557055981 hasRelatedWork W2418129918 @default.
• W2557055981 hasRelatedWork W2549482608 @default.
• W2557055981 hasRelatedWork W2587798070 @default.
• W2557055981 hasRelatedWork W2588332746 @default.
• W2557055981 hasRelatedWork W2592659745 @default.
• W2557055981 hasRelatedWork W2752390106 @default.
• W2557055981 hasRelatedWork W2983015496 @default.
• W2557055981 hasRelatedWork W3023094998 @default.
• W2557055981 isParatext "false" @default.
• W2557055981 isRetracted "false" @default.
• W2557055981 magId "2557055981" @default.
• W2557055981 workType "article" @default.